Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, Missouri.
Cancer Immunol Res. 2024 Sep 3;12(9):1136-1146. doi: 10.1158/2326-6066.CIR-24-0251.
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.
近年来,基因组编辑技术取得了显著的进展,使对外源和内源性基因的精确调控成为可能。这些进展已经广泛应用于人类 T 淋巴细胞的工程改造,为癌症患者带来了改变治疗方式的疗法,并为多种非恶性疾病带来了合成免疫细胞疗法的希望。许多不同的概念和技术方法已被用于编辑 T 细胞基因组,但很少有报道针对哪种技术在制造、基因编辑和转基因表达方面最有效的靶向评估。通过广泛的比较评估,我们确定了在制造的关键阶段最有效地增强研究规模和临床前 T 细胞产品工程的方法。